Results 21 to 30 of about 19,211 (198)

Association of CYP2C9*2 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population

Biomedicines, 2023
Polymorphism in cytochrome P450 (CYP) 2C9 enzyme is known to cause significant inter-individual differences in drug response and occurrence of adverse drug reactions.
Asif Jan, Muhammad Saeed, Ramzi A. Mothana, Tahir Muhammad, Naveed Rahman, Abdullah R. Alanzi, Rani Akbar   +6 more
doaj   +1 more source

High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid® Substrates [PDF]

SLAS Discovery, 2004
CYP2C9 is a genetically polymorphic human cytochrome P450 isozyme involved in the oxidative metabolism of many drugs, including nonsteroidal anti-inflammatory compounds. Individuals genotyped heterozygous or homozygous for CYP2C9 allelic variants have demonstrated altered metabolism of some drugs primarily metabolized by CYP2C9.
Bryan D, Marks, David V, Thompson, Tony A, Goossens, Olga V, Trubetskoy   +3 more
openaire   +2 more sources

Strain‐Release Pentafluorosulfanylation of Carbonyl‐Containing Disubstituted Bicyclobutanes: A Fortuitous Path to SF5‐Containing Oxa[2.1.1]bicyclohexanes

Angewandte Chemie, EarlyView.
A regio‐ and diastereoselective method for strain‐release pentafluorosulfanylation of carbonyl‐containing 1,3‐disubstituted [1.1.0]bicyclobutanes (BCBs) was developed that led to several fortuitous discoveries. For instance, the resultant SF5‐cyclobutanes (SF5‐CBs) exhibit close SF5⋯C═X contacts (X = C, N, O) and provide synthetic access to a new class
Alexander M. Stephens, Jake Anthony Olvera, Yannick Kraemer, Tyson Vu, Wang‐Yeuk Kong, Sudiksha Chaturvedi, Jeffrey M. Wang, Lauren M. Holder, Dean J. Tantillo, Cody Ross Pitts   +9 more
wiley   +2 more sources

Functional Characterisation of Human CYP2C9 Allelic Variants in COS-7 cells

Frontiers in Pharmacology, 2016
Variability in activity of CYP2C9, which is involved in the metabolism of approximately 15% of current therapeutic drugs, is an important contributor to interindividual differences in drug response.
Huihui eDu, Zhiyun eWei, Yucai eYan, Yuyu eXiong, Xiaoqing eZhang, Lu eShen, Yunfeng eRuan, Xi eWu, Qingqing eXu, Lin eHe, Shengying eQin   +10 more
doaj   +1 more source

CYP2C9*2 and CYP2C9*3 Alleles Confer a Lower Risk for Myocardial Infarction [PDF]

Clinical Chemistry, 2004
Cytochrome P-450 (CYP) genes encode for membrane-bound, heme-containing enzymes that catalyze the oxidation of various drugs and endogenous substrates such as vitamin D, steroids, or fatty acids, including arachidonic acid (AA). CYP enzymes of the P-450 2C9 subfamily are produced in the liver, are responsible for 50% of the epoxygenase activity in ...
Marion, Funk, Georg, Endler, Renate, Freitag, Johann, Wojta, Kurt, Huber, Christine, Mannhalter, Raute, Sunder-Plassmann   +6 more
openaire   +2 more sources

Lack of Association of Clinical Factors (SAMe-TTR) with / Genotype and Anticoagulation Control Quality [PDF]

Journal of Stroke, 2015
Background and PurposeAdvantages of new oral anticoagulations may be greater in atrial fibrillation (AF) patients of poor anticoagulation control with warfarin.
Yun Kyung Park, Mi ji Lee, Jae Ha Kim, Suk Jae Kim, June Soo Kim, Soo-Youn Lee, Oh Young Bang   +6 more
doaj   +1 more source

Modulating effect of Cu(II) complexes with enamine and tetrazole derivatives on CYP2C and CYP3A and their cytotoxic and antiproliferative properties in HepG2 spheroids

Acta Biomedica Scientifica, 2022
CYP2C and CYP3A cytochromes are induced by a variety of compounds and affect the pharmacokinetics and pharmacodynamics of a large number of drugs. Currently, the possibility of using copper coordination compounds in antitumor therapy is being actively ...
L. S. Klyushova, Yu. A. Golubeva, V. A. Vavilin, A. Yu. Grishanova   +3 more
doaj   +1 more source

CYP2C9 polymorphisms are associated with phenytoin toxicity in South-Indian epileptic patients

Journal of Dr. NTR University of Health Sciences, 2020
Background and Aims: The contribution of CYP2C9 in phenytoin metabolism is generally modest, but it increases with increasing serum phenytoin concentration.
Rakesh Reddy Reddigari, S V Naveen Prasad, Vengamma Bhuma, P VGK Sarma, Appa Rao Anumolu   +4 more
doaj   +1 more source

Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants

Frontiers in Systems Biology
Losartan is a selective angiotensin II AT1-receptor antagonist for the treatment of arterial hypertension and heart failure. It is converted to a pharmacologically active metabolite carboxylosartan (E-3174) in the liver mainly by CYP2C9 enzyme, a member ...
Dmitry Babaev, Elena Kutumova, Elena Kutumova, Fedor Kolpakov, Fedor Kolpakov   +4 more
doaj   +1 more source

Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery

Рациональная фармакотерапия в кардиологии, 2021
Aim. The aim of the study was to evaluate the efficacy and safety of ketoprofen as an analgesic therapy in patients with CYP2C9*2 (430C>T) rs179985 and CYP2C9*3 (1075A>C) rs1057910 gene polymorphisms after cardiac surgery.Material and methods.
T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Zh. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. A. Grishina, D. A. Sychev   +11 more
doaj   +1 more source